The patent dispute on CRISPR between UC/Jennifer Doudna and The Broad/Feng Zhang has been the subject of major attention including in a recent piece on Stanford Center for Law & Biosciences Blog. There is a lot of confusion over this important CRISPR dispute so I turned to a patent expert for their take on this via an interview …
Patent expert weighs in on CRISPR dispute between UC & Broad Read More »
Sometimes it seems like a bunch of stuff in one area, like with CRISPR this week, happens all of a sudden in science. A bunch of fairly high-profile gene editing pubs came out. They generated a lot of news reports. Other news in this arena popped up too, all within a few days. In vivo …
CRISPR update: lots of new pubs, news, & maybe a patent finale Read More »
There’s a lot going on in the world of stem cells making for many striking headlines lately. Here are some stem cell headlines that caught my attention. Haploid Stem Cells Created. Could these cells be used to make germ cells? Charlatans and snake-oil salesmen ‘hijacking stem cell therapies’ in Australia In the CRISPR patent fight, the Broad Institute gains edge. The CRISPR-Cas9 patent …
Stem cell headlines: half a genome, Australian snake oil, CRISPR patent battle Read More »
Who really invented CRISPR? If it was many people and labs, who did it first and who deserves the credit? When things like Nobel Prizes and Patents get decided on CRISPR-Cas9, who will be for lack of a better way of putting it, the winners and the losers? It’s not a trivial question and despite …
A hunch on that CRISPR patent battle as it heats up Read More »
A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, …
New #CRISPR updates: Editas to go public, patent issues, dragons & more Read More »
There is no hotter technology than CRISPR-Cas9 gene editing tools. Perhaps it is not surprising then that there is a patent dispute over it, which falls into two camps: (1) Jennifer Doudna & Emmanuelle Charpentier, and (2) Feng Zhang. Who deserves the intellectual property for use of CRISPR-Cas9 in human cells? Take our poll.
A new patent dispute has exploded in the stem cell field related to induced pluripotent stem (iPS) cells. What’s going on? In 2006, Shinya Yamanaka reported cellular reprogramming to create mouse induced pluripotent stem (iPS) cells in Cell and the next year multiple groups along with Yamanaka’s reported creating human iPS cells. It’s no exaggeration …
Challenge tries to cancel Yamanaka iPS cell patent Read More »
Has it really been 10 years since induced pluripotent stem cells (aka IPS cells or IPSC) came onto the scene in the stem cell field? Yes, it was a decade ago that now Nobel Laureate Shinya Yamanaka (山中伸弥) published that seminal Cell paper on reprogramming to make mouse IPS cells and then human IPS cells …
Yamanaka’s baby turns 10: ten IPS cell hot button bullet points Read More »
Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can …
In Depth Report from April 29th Paris Human Gene Edit Meeting Read More »
CRISPR is the hottest new biotechnology and the top development of 2015 according to Science Magazine. What will the new year of 2016 bring on the CRISPR front? It’s clear there will be more meetings on CRISPR ethics and policy (heck, we are having one right here at UC Davis on May 26), but what …